BRD2 and metabolic syndrome: Admittedly ambitious, we envisage, in a best-case scenario, and if mouse data translate into people, of treating four diseases that affect millions of women and men worldwide—namely obesity, osteoporosis, dyslipidemia, and neurodegeneration—with a single multipurpose FSH-blocking agent.